HK1223839A1 - 用於多發性硬化症的樹突細胞 靶向免疫治療劑 - Google Patents
用於多發性硬化症的樹突細胞 靶向免疫治療劑Info
- Publication number
- HK1223839A1 HK1223839A1 HK16112194.1A HK16112194A HK1223839A1 HK 1223839 A1 HK1223839 A1 HK 1223839A1 HK 16112194 A HK16112194 A HK 16112194A HK 1223839 A1 HK1223839 A1 HK 1223839A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- asgpr
- multiple sclerosis
- dendritic cell
- immunotherapeutics
- targeting immunotherapeutics
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title 1
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361841094P | 2013-06-28 | 2013-06-28 | |
PCT/US2014/044711 WO2014210540A1 (en) | 2013-06-28 | 2014-06-27 | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1223839A1 true HK1223839A1 (zh) | 2017-08-11 |
Family
ID=52142738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16112194.1A HK1223839A1 (zh) | 2013-06-28 | 2016-10-24 | 用於多發性硬化症的樹突細胞 靶向免疫治療劑 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20160296609A1 (zh) |
EP (1) | EP3013362B1 (zh) |
JP (1) | JP6566941B2 (zh) |
CN (1) | CN105555303A (zh) |
AU (1) | AU2014302082B2 (zh) |
CA (1) | CA2916694C (zh) |
HK (1) | HK1223839A1 (zh) |
IL (1) | IL243179B (zh) |
WO (1) | WO2014210540A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2677844T3 (es) | 2010-10-19 | 2018-08-07 | The Regents Of The University Of Colorado, A Body Corporate | Péptidos para modular la actividad de linfocitos T y usos de los mismos |
EP3142691A4 (en) * | 2014-05-16 | 2018-04-11 | Baylor Research Institute | Methods and compositions for treating autoimmune and inflammatory conditions |
US11793854B2 (en) * | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
EP4135742A2 (en) | 2020-04-17 | 2023-02-22 | Op-T Llc | Bioactive peptides and methods of use thereof |
WO2023159140A2 (en) * | 2022-02-17 | 2023-08-24 | Adimab, Llc | Anti-asgr1 polypeptides and methods of use for immune tolerance |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
JPH049249A (ja) | 1990-04-27 | 1992-01-14 | Kusuda:Kk | 塗型剤吹き付け機 |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
WO1994019935A1 (en) | 1993-03-09 | 1994-09-15 | Genzyme Corporation | Isolation of components of interest from milk |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
US6235888B1 (en) | 1994-10-05 | 2001-05-22 | The General Hospital Corporation | Hepatitis C virus vaccine |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US20030105303A1 (en) | 1996-12-06 | 2003-06-05 | Schering Corporation, A New Jersey Corporation | Isolated mammalian monocyte cell genes; related reagents |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
EP1118669A3 (en) | 1999-12-17 | 2001-08-29 | Unilever Plc | Production of camelid antibodies in plants |
US6651655B1 (en) | 2000-01-18 | 2003-11-25 | Quadrant Technologies Limited | Inhaled vaccines |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
AU2003248791A1 (en) | 2002-07-03 | 2005-11-09 | Oncovir, Inc. | Method for preparation of poly-iclc and uses thereof |
SG173218A1 (en) | 2003-06-12 | 2011-08-29 | Alnylam Pharmaceuticals Inc | Conserved hbv and hcv sequences useful for gene silencing |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
TWI422594B (zh) * | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑 |
NZ578657A (en) | 2007-02-02 | 2012-02-24 | Baylor Res Inst | Multivariable antigens complexed with targeting humanized monoclonal antibody |
NZ578696A (en) | 2007-02-02 | 2012-01-12 | Baylor Res Inst | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
NZ589341A (en) | 2007-02-23 | 2012-02-24 | Baylor Res Inst | Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1) |
EP2129692A4 (en) | 2007-02-23 | 2010-12-15 | Baylor Res Inst | ACTIVATION OF CELLS WITH HUMAN ANTIGENES BY CLEC-6 |
CA2717659C (en) | 2007-02-23 | 2017-08-22 | Baylor Research Institute | Therapeutic applications of activation of human antigen-presenting cells through dectin-1 |
WO2010009346A2 (en) | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
US20120076831A1 (en) * | 2009-01-20 | 2012-03-29 | Stephen Miller | Compositions and methods for induction of antigen-specific tolerance |
JP5883653B2 (ja) | 2009-03-10 | 2016-03-15 | ベイラー リサーチ インスティテュートBaylor Research Institute | 抗原提示細胞ターゲティング抗ウイルスワクチン |
CN105884903B (zh) | 2009-03-10 | 2019-12-06 | 贝勒研究院 | 靶向抗原呈递细胞的疫苗 |
MX2011009438A (es) | 2009-03-10 | 2012-04-02 | Baylor Res Inst | Anticuerpos anti-cd40 y usos de los mismos. |
BR112012005713A2 (pt) | 2009-09-14 | 2019-09-24 | Baylor Res Institute | vacinas direcionadas a célula langerhans. |
WO2011044452A2 (en) * | 2009-10-08 | 2011-04-14 | President And Fellows Of Harvard College | Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences |
JP2013525496A (ja) | 2010-05-07 | 2013-06-20 | ベイラー リサーチ インスティテュート | ヒトcd8+t細胞の樹状細胞免疫受容体(dcir)媒介クロスプライミング |
US20120029907A1 (en) * | 2010-07-27 | 2012-02-02 | Angela Loggins | myMedicalpen |
CA2807585A1 (en) | 2010-08-13 | 2012-02-16 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
US8541108B2 (en) * | 2010-09-27 | 2013-09-24 | Xerox Corporation | Fuser member |
US20120121592A1 (en) | 2010-10-13 | 2012-05-17 | Baylor Research Institute | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells |
US20120128710A1 (en) | 2010-11-02 | 2012-05-24 | Baylor Research Institute | Enhancement of Pathogen-Specific Memory Th17 Cell Responses |
WO2012118622A1 (en) | 2011-02-19 | 2012-09-07 | Baylor Research Institute | Diagnostic and therapeutic uses for b cell maturation antigen |
AR085633A1 (es) | 2011-03-08 | 2013-10-16 | Baylor Res Inst | Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos |
CA2830987A1 (en) | 2011-03-22 | 2012-09-27 | Baylor Research Institute | Dendritic cells (dcs) targeting for tuberculosis (tb) vaccine |
WO2012144512A1 (ja) * | 2011-04-22 | 2012-10-26 | 国立大学法人京都大学 | 関節リウマチの新規遺伝因子としてのミエリン塩基性蛋白の利用 |
CN104010664A (zh) * | 2011-09-26 | 2014-08-27 | 苏黎世大学数学和自然科学部 | 用于治疗多发性硬化的apc介导的耐受诱导 |
WO2013160865A1 (en) | 2012-04-26 | 2013-10-31 | Toleranzia Ab | Immunotolerizing fusion proteins for treatment of multiple sclerosis |
US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2014
- 2014-06-27 CA CA2916694A patent/CA2916694C/en active Active
- 2014-06-27 EP EP14817259.6A patent/EP3013362B1/en active Active
- 2014-06-27 AU AU2014302082A patent/AU2014302082B2/en active Active
- 2014-06-27 CN CN201480047070.0A patent/CN105555303A/zh active Pending
- 2014-06-27 WO PCT/US2014/044711 patent/WO2014210540A1/en active Application Filing
- 2014-06-27 JP JP2016524262A patent/JP6566941B2/ja active Active
- 2014-06-27 US US14/901,617 patent/US20160296609A1/en not_active Abandoned
-
2015
- 2015-12-17 IL IL243179A patent/IL243179B/en unknown
-
2016
- 2016-10-24 HK HK16112194.1A patent/HK1223839A1/zh unknown
-
2021
- 2021-09-14 US US17/447,607 patent/US20220054609A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3013362B1 (en) | 2021-08-04 |
EP3013362A4 (en) | 2017-02-15 |
US20220054609A1 (en) | 2022-02-24 |
IL243179B (en) | 2021-07-29 |
IL243179A0 (en) | 2016-03-31 |
WO2014210540A1 (en) | 2014-12-31 |
EP3013362A1 (en) | 2016-05-04 |
US20160296609A1 (en) | 2016-10-13 |
CA2916694A1 (en) | 2014-12-31 |
JP2016523917A (ja) | 2016-08-12 |
JP6566941B2 (ja) | 2019-08-28 |
CA2916694C (en) | 2023-01-17 |
CN105555303A (zh) | 2016-05-04 |
AU2014302082A1 (en) | 2016-01-21 |
AU2014302082B2 (en) | 2019-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1222187A1 (zh) | 含硅烷的羧基封端的聚合物 | |
IL236563A0 (en) | Direct search-driven contact | |
EP3065716C0 (en) | FORMULATIONS | |
EP2838564A4 (en) | ALPHA-D-GLUCANES HIGHLY RAMIFIED | |
GB201215193D0 (en) | Order delivery system | |
HK1204973A1 (zh) | 雙氯芬酸製劑 | |
EP2872853A4 (en) | MECHANICAL TRACKING SYSTEM | |
ZA201507661B (en) | Racecadotril lipid compositions | |
GB201319792D0 (en) | Formulations | |
EP2988354A4 (en) | FUEL CELL SYSTEM | |
HK1223839A1 (zh) | 用於多發性硬化症的樹突細胞 靶向免疫治療劑 | |
EP2916451A4 (en) | ELECTRICITY PRODUCTION SYSTEM | |
IL244508A0 (en) | intrauterine delivery system | |
EP2827402A4 (en) | PERFORMANCE MEMORY | |
HK1214951A1 (zh) | 眼用製劑 | |
EP2810960A4 (en) | POLYMERIZATION CATALYST COMPOSITION FOR MONOMER WITH CONJUGATED SERV | |
EP3005266A4 (en) | CONCEPTS FOR ADVERTISING OPPORTUNITIES | |
IL235196B (en) | Line charge system | |
PL2908835T3 (pl) | Stabilne formulacje | |
SG10201609440WA (en) | Multi-additive delivery system | |
EP2852012A4 (en) | DEVICE WITH LASER EFFECT | |
GB201315602D0 (en) | Bend stiffener | |
EP3073559A4 (en) | FUEL CELL SYSTEM | |
GB201810509D0 (en) | Charging system | |
GB201306981D0 (en) | Delivery system |